Head-to-head · computed 2026-08-11
NovoCare Pharmacy (Wegovy) vs Willow
NovoCare Pharmacy (Wegovy): Novo Nordisk's direct cash pharmacy sells FDA-approved Wegovy pens at $349/month across standard doses ($399 for the 7.2 mg HD pen), with a $199 introductory price on the first two starter-dose fills and oral Wegovy tablets from $149/month. It is the FDA-approved semaglutide price floor and the benchmark for every compounded semaglutide quote. Willow: Willow sells patient-specific 503A compounded tirzepatide at a flat $399 a month at every dose, telehealth and shipping included, in 33 states as of mid-2026 reporting.
Tirzepatide
Only Willow offers tirzepatide ($399 a month billed monthly); NovoCare Pharmacy (Wegovy) does not, so there is no contest to score.
Semaglutide
Only NovoCare Pharmacy (Wegovy) offers semaglutide ($349 a month billed monthly); Willow does not, so there is no contest to score.
Where the structures genuinely differ
On dose economics, Willow is dose-flat — the price survives titration — while NovoCare Pharmacy (Wegovy)'s pricing can move with the dose, a difference that compounds through a standard escalation schedule and matters most to buyers expecting to reach the higher maintenance doses. On verifiability, NovoCare Pharmacy (Wegovy) names its dispensing pharmacy — which means the fifteen-minute license-and-records check is possible — while Willow's pharmacy is not disclosed on record, the single structural fact this desk weighs heaviest after the FDA's 2026 letters cited exactly that practice.
Structure, side by side
NovoCare Pharmacy (Wegovy)
- MembershipNone
- Dose policyPen $349 (0.25–2.4 mg), Wegovy HD 7.2 mg $399; new-patient intro $199 for first two fills of 0.25/0.5 mg through Dec 31, 2026; oral Wegovy $149 (1.5 mg and 4 mg; 4 mg offer through Aug 31, 2026, then $199) up to ~$299 at higher tablet doses
- CommitmentNone
- CancellationNo subscription lock
- PharmacyCoAssist Pharmacy d/b/a NovoCare Pharmacy
Willow
- MembershipNone
- Dose policyDose-flat per captured reporting: flat $399 at every dose
- CommitmentMonthly
- CancellationPer published terms; confirm at checkout
- PharmacyPatient-specific 503A compounding (pharmacy unnamed on captured materials)
What our desk is watching on each
NovoCare Pharmacy (Wegovy): The $199 intro and the $149 oral tier both carry published expiration dates; the durable numbers are $349 pen / $399 HD.
Willow: Reported from a June 15, 2026 comparison table (MenoMellow) — our own capture pending; the flat-at-every-dose structure and 33-state footprint both carry that single-source status until independently confirmed. Pharmacy unnamed on captured materials.
Questions people ask
Is NovoCare Pharmacy (Wegovy) or Willow cheaper in 2026?
The tirzepatide and semaglutide verdict blocks above give the computed answer at the maintenance basis, with the verification status of each figure; the short version is that whichever program's all-in monthly number is lower on this page is cheaper on the evidence we hold today, and both rows carry capture dates so you can judge freshness.
What does NovoCare Pharmacy (Wegovy) vs Willow miss that checkout will show?
Taxes, state availability, current promotions, and any dose surcharge introduced after our capture date. Screenshot the order summary before paying — that capture, not any comparison page, is your contract.
Why do you compare at the maintenance dose instead of the starting dose?
Because starter pricing lasts one or two months and maintenance pricing lasts the rest of the year; comparing starts against maintenances is the single most common way GLP-1 comparisons mislead.
Both records live in the normalized database; re-run the math yourself from the downloads. Full record pages: NovoCare Pharmacy (Wegovy) · Willow. Official sites: NovoCare Pharmacy (Wegovy) ↗ · Willow ↗. Nothing here is medical advice.